An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia
Diseases and Conditions Researched
Leukemia, not otherwise specified; Myeloid and Monocytic Leukemia
What is the purpose of this trial?
The primary objective is to investigate the maximum tolerated dose (MTD), safety and efficacy of volasertib in combination with decitabine in patients with acute myeloid leukaemia (AML).
Click here for detailed participation information for this trial.
|Sponsor:||Boehringer Ingelheim Pharmaceuticals, Inc.|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.